156 related articles for article (PubMed ID: 18221909)
1. CD4+ T helper responses in squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Yamamoto T; Furuya N; Whiteside TL; Masuyama K
Oral Oncol; 2008 Sep; 44(9):870-7. PubMed ID: 18221909
[TBL] [Abstract][Full Text] [Related]
2. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.
Chikamatsu K; Sakakura K; Takahashi G; Okamoto A; Furuya N; Whiteside TL; DeLeo AB; Masuyama K
Cancer Immunol Immunother; 2009 Sep; 58(9):1441-8. PubMed ID: 19184003
[TBL] [Abstract][Full Text] [Related]
4. Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck.
Ito D; Visus C; Hoffmann TK; Balz V; Bier H; Appella E; Whiteside TL; Ferris RL; DeLeo AB
Int J Cancer; 2007 Jun; 120(12):2618-24. PubMed ID: 17294448
[TBL] [Abstract][Full Text] [Related]
5. Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.
Hoffmann TK; Nakano K; Elder EM; Dworacki G; Finkelstein SD; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2000 Nov; 165(10):5938-44. PubMed ID: 11067956
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide.
Röpke M; Hald J; Guldberg P; Zeuthen J; Nørgaard L; Fugger L; Svejgaard A; Van der Burg S; Nijman HW; Melief CJ; Claesson MH
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14704-7. PubMed ID: 8962118
[TBL] [Abstract][Full Text] [Related]
7. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
[TBL] [Abstract][Full Text] [Related]
8. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
9. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
10. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
11. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
12. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.
Chikamatsu K; Nakano K; Storkus WJ; Appella E; Lotze MT; Whiteside TL; DeLeo AB
Clin Cancer Res; 1999 Jun; 5(6):1281-8. PubMed ID: 10389910
[TBL] [Abstract][Full Text] [Related]
13. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
[TBL] [Abstract][Full Text] [Related]
14. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
Albers AE; Ferris RL; Kim GG; Chikamatsu K; DeLeo AB; Whiteside TL
Cancer Immunol Immunother; 2005 Nov; 54(11):1072-81. PubMed ID: 15959774
[TBL] [Abstract][Full Text] [Related]
15. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
16. Phenotype of p53 wild-type epitope-specific T cells in the circulation of patients with head and neck cancer.
Albers AE; Qian X; Kaufmann AM; Mytilineos D; Ferris RL; Hoffmann TK; DeLeo AB
Sci Rep; 2018 Jul; 8(1):10716. PubMed ID: 30013227
[TBL] [Abstract][Full Text] [Related]
17. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
[TBL] [Abstract][Full Text] [Related]
18. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
20. MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.
Cesson V; Rivals JP; Escher A; Piotet E; Thielemans K; Posevitz V; Dojcinovic D; Monnier P; Speiser D; Bron L; Romero P
Cancer Immunol Immunother; 2011 Jan; 60(1):23-35. PubMed ID: 20857101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
